여성 건강 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)
상품코드:1402887
리서치사:Transparency Market Research
발행일:2023년 11월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
한글목차
여성 건강 시장 - 보고서의 범위
TMR의 세계 여성 건강 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻을 수 있는 기회를 연구하고 있습니다. 이 보고서는 세계 여성 건강 시장의 수익을 제공합니다. 2017년부터 2031년까지, 2023년을 기준 연도, 2031년을 예측 연도로 간주합니다. 이 보고서는 또한 2023년부터 2031년까지 세계 여성 건강 시장의 복합 연간 성장률(CAGR %)을 제공합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 대부분의 조사 활동은 애널리스트가 주요 오피니언 리더, 업계 리더 및 오피니언 메이커를 인터뷰하는 방식으로 이루어졌습니다. 2차 조사에는 여성 건강 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.
시장 스냅샷
2023년 시장 가치
778억 달러
2031년 시장 가치
1,309억 달러
CAGR
5.5%
이 보고서는 세계 여성 건강 시장의 경쟁 구도를 자세히 조사합니다. 세계 여성 건강 시장에서 활동하는 주요 기업이 식별되고 각 기업은 다양한 속성 측면에서 프로파일링됩니다. 회사 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 여성 건강 시장 기업의 속성입니다.
목차
제1장 주요 요약
제2장 가정과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
시장 세분화
개요
시장 역학
세계 시장 분석과 예측, 2023-2031년
제5장 중요한 인사이트
파이프라인 분석
여성에게 자주 있는 건강 문제 리스트
주요 국가의 세계 질병 유병률과 이환율
COVID-19 감염증 팬데믹이 업계에 미치는 영향
제6장 시장 분석과 예측 : 치료 유형별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 치료 유형별, 2023-2031년
호르몬 치료
에스트로겐 요법
프로게스틴 요법
병용요법
갑상선 치환 요법
부갑상선호르몬 요법
기타
비호르몬 치료
표적요법제
항생제
비스포스포네이트
기타
시장 매력 : 치료 유형별
제7장 세계 시장 분석과 예측 : 질환 적응별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 질환 적응별, 2023-2031년
암
유방암
자궁경부암
난소암
갑상선기능저하증
폐경후 증후군
골다공증
피임
자궁근종
요로 감염
기타
시장 매력 : 질환별
제8장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별, 2023-2031년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력 : 지역별
제9장 북미 시장 분석과 예측
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 상황
시장 기업 - 경쟁 매트릭스(기업 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
Eli Lilly and Company
Novartis AG
Pfizer, Inc.
Merck &Co., Inc.
Novo Nordisk A/S
Amgen Inc.
AstraZeneca
F. Hoffmann-La Roche Ltd
Sanofi
Allergan Plc.
GlaxoSmithKline plc
Lupin Pharmaceuticals, Inc.
ksm
영문 목차
영문목차
Women's Health Market - Scope of Report
TMR's report on the global women's health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global women's health market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global women's health market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the women's health market.
Market Snapshot
Market Value in 2023
US$ 77.8 Bn
Market Value in 2031
US$ 130.9 Bn
CAGR
5.5%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global women's health market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global women's health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global women's health market.
The report delves into the competitive landscape of the global women's health market. Key players operating in the global women's health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global women's health market profiled in this report.
Key Questions Answered in Global women's health Market Report:
What is the sales/revenue generated by women's health across all regions during the forecast period?
What are the opportunities in the global women's health market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Women's Health Market - Research Objectives and Research Approach
The comprehensive report on the global women's health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global women's health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global women's health market.
Table of Contents
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Women's Health Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Women's Health Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Common Health Issues Among Women
5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
5.4. COVID-19 Pandemic Impact on Industry
6. Women's Health Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2023-2031
6.3.1. Hormonal Treatment
6.3.1.1. Estrogen Therapy
6.3.1.2. Progestin Therapy
6.3.1.3. Combination Therapy
6.3.1.4. Thyroid Replacement Therapy
6.3.1.5. Parathyroid Hormone Therapy
6.3.1.6. Others
6.3.2. Non-Hormonal Treatment
6.3.2.1. Targeted Therapy Drugs
6.3.2.2. Antibiotics
6.3.2.3. Bisphosphonates
6.3.2.4. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Women's Health Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2023-2031
7.3.1. Cancer
7.3.1.1. Breast Cancer
7.3.1.2. Cervical Cancer
7.3.1.3. Ovarian Cancer
7.3.2. Hypothyroidism
7.3.3. Post-Menopausal Syndrome
7.3.4. Osteoporosis
7.3.5. Contraception
7.3.6. Uterine Fibroid
7.3.7. Urinary Tract Infection
7.3.8. Others
7.4. Market Attractiveness, by Disease Indication
8. Global Women's Health Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Women's Health Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2023-2031
9.2.1. Hormonal Treatment
9.2.1.1. Estrogen Therapy
9.2.1.2. Progestin Therapy
9.2.1.3. Combination Therapy
9.2.1.4. Thyroid Replacement Therapy
9.2.1.5. Parathyroid Hormone Therapy
9.2.1.6. Others
9.2.2. Non-Hormonal Treatment
9.2.2.1. Targeted Therapy Drugs
9.2.2.2. Antibiotics
9.2.2.3. Bisphosphonates
9.2.2.4. Others
9.3. Market Value Forecast, by Disease Indication, 2023-2031
9.3.1. Cancer
9.3.1.1. Breast Cancer
9.3.1.2. Cervical Cancer
9.3.1.3. Ovarian Cancer
9.3.2. Hypothyroidism
9.3.3. Post-Menopausal Syndrome
9.3.4. Osteoporosis
9.3.5. Contraception
9.3.6. Uterine Fibroid
9.3.7. Urinary Tract Infection
9.3.8. Others
9.4. Market Value Forecast, by Country, 2023-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1.1. By Treatment Type
9.5.1.2. By Disease Indication
9.5.1.3. By Country
10. Europe Women's Health Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2023-2031
10.2.1. Hormonal Treatment
10.2.1.1. Estrogen Therapy
10.2.1.2. Progestin Therapy
10.2.1.3. Combination Therapy
10.2.1.4. Thyroid Replacement Therapy
10.2.1.5. Parathyroid Hormone Therapy
10.2.1.6. Others
10.2.2. Non-Hormonal Treatment
10.2.2.1. Targeted Therapy Drugs
10.2.2.2. Antibiotics
10.2.2.3. Bisphosphonates
10.2.2.4. Others
10.3. Market Value Forecast, by Disease Indication, 2023-2031
10.3.1. Cancer
10.3.1.1. Breast Cancer
10.3.1.2. Cervical Cancer
10.3.1.3. Ovarian Cancer
10.3.2. Hypothyroidism
10.3.3. Post-Menopausal Syndrome
10.3.4. Osteoporosis
10.3.5. Contraception
10.3.6. Uterine Fibroid
10.3.7. Urinary Tract Infection
10.3.8. Others
10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1.1. By Treatment Type
10.5.1.2. By Disease Indication
10.5.1.3. By Country/Sub-region
11. Asia Pacific Women's Health Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2023-2031
11.2.1. Hormonal Treatment
11.2.1.1. Estrogen Therapy
11.2.1.2. Progestin Therapy
11.2.1.3. Combination Therapy
11.2.1.4. Thyroid Replacement Therapy
11.2.1.5. Parathyroid Hormone Therapy
11.2.1.6. Others
11.2.2. Non-Hormonal Treatment
11.2.2.1. Targeted Therapy Drugs
11.2.2.2. Antibiotics
11.2.2.3. Bisphosphonates
11.2.2.4. Others
11.3. Market Value Forecast, by Disease Indication, 2023-2031
11.3.1. Cancer
11.3.1.1. Breast Cancer
11.3.1.2. Cervical Cancer
11.3.1.3. Ovarian Cancer
11.3.2. Hypothyroidism
11.3.3. Post-Menopausal Syndrome
11.3.4. Osteoporosis
11.3.5. Contraception
11.3.6. Uterine Fibroid
11.3.7. Urinary Tract Infection
11.3.8. Others
11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Disease Indication
11.5.3. By Country/Sub-region
12. Latin America Women's Health Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2023-2031
12.2.1. Hormonal Treatment
12.2.1.1. Estrogen Therapy
12.2.1.2. Progestin Therapy
12.2.1.3. Combination Therapy
12.2.1.4. Thyroid Replacement Therapy
12.2.1.5. Parathyroid Hormone Therapy
12.2.1.6. Others
12.2.2. Non-Hormonal Treatment
12.2.2.1. Targeted Therapy Drugs
12.2.2.2. Antibiotics
12.2.2.3. Bisphosphonates
12.2.2.4. Others
12.3. Market Value Forecast, by Disease Indication, 2023-2031
12.3.1. Cancer
12.3.1.1. Breast Cancer
12.3.1.2. Cervical Cancer
12.3.1.3. Ovarian Cancer
12.3.2. Hypothyroidism
12.3.3. Post-Menopausal Syndrome
12.3.4. Osteoporosis
12.3.5. Contraception
12.3.6. Uterine Fibroid
12.3.7. Urinary Tract Infection
12.3.8. Others
12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Disease Indication
12.5.3. By Country/Sub-region
13. Middle East & Africa Women's Health Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2023-2031
13.2.1. Hormonal Treatment
13.2.1.1. Estrogen Therapy
13.2.1.2. Progestin Therapy
13.2.1.3. Combination Therapy
13.2.1.4. Thyroid Replacement Therapy
13.2.1.5. Parathyroid Hormone Therapy
13.2.1.6. Others
13.2.2. Non-Hormonal Treatment
13.2.2.1. Targeted Therapy Drugs
13.2.2.2. Antibiotics
13.2.2.3. Bisphosphonates
13.2.2.4. Others
13.3. Market Value Forecast, by Disease Indication, 2023-2031
13.3.1. Cancer
13.3.1.1. Breast Cancer
13.3.1.2. Cervical Cancer
13.3.1.3. Ovarian Cancer
13.3.2. Hypothyroidism
13.3.3. Post-Menopausal Syndrome
13.3.4. Osteoporosis
13.3.5. Contraception
13.3.6. Uterine Fibroid
13.3.7. Urinary Tract Infection
13.3.8. Others
13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Disease Indication
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Eli Lilly and Company
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Merck & Co., Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Novo Nordisk A/S
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Amgen Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. AstraZeneca
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. F. Hoffmann-La Roche Ltd
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Sanofi
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Allergan Plc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. GlaxoSmithKline plc
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Lupin Pharmaceuticals, Inc.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
